Einzeltreffer — DigiBib

Introduction: Carbon monoxide (CO) released from CORM-2 has anti-inflammatory function, but the critical molecule mediating the inflammation inhibition has not been elucidated. Previous studies indicate that CORM-2 can activate Nrf2, a key transcription factor regulating host defense against oxidative stress and inflammation-related disorders. In this study we use Nrf2 knockout mice to determine the role of Nrf2 in mediating the CO anti-inflammatory action.

Methods: We compared CORM-2's inhibiting effect on pro-inflammatory cytokine expressions (TNF-α, IL-1β and IL-6 and iNOS) in primary peritoneal macrophages, mouse liver and brain tissues from Nrf2(+/+) and Nrf2(-/-) mice. We further assayed the inflammatory cell infiltration in both liver and brain tissues of the Nrf2(+/+) and Nrf2(-/-) mice. Finally, we examined CORM's influence on mouse mortality in a mouse sepsis model.

Results: Our results showed that CORM-2 dramatically inhibited the expression of pro-inflammatory cytokines in Nrf2(+/+) mice, but not in Nrf2(-/-) mice. Furthermore CORM-2 substantially decreased LPS-induced mouse mortality of Nrf2(+/+) mice, but not of Nrf2(-/-) mice.

Conclusion: We conclude that Nrf2 is indispensable for CORM-2 inhibition of LPS-induced inflammation.

Titel:	Nrf2 is essential for the anti-inflammatory effect of carbon monoxide in LPS-induced inflammation.
Autor/in / Beteiligte Person:	Qin, S ; Du, R ; Yin, S ; Liu, X ; Xu, G ; Cao, W
Link:	Full Text Finder (Volltext)
Zeitschrift:	Inflammation research : official journal of the European Histamine Research Society ... [et al.], Jg. 64 (2015-07-01), Heft 7, S. 537-48
Veröffentlichung:	Basel, Switzerland : Birkhäuser, c1995-, 2015
Medientyp:	academicJournal
ISSN:	1420-908X (electronic)
DOI:	10.1007/s00011-015-0834-9
Schlagwort:	Animals Brain drug effects Brain metabolism Cytokines biosynthesis Female Lipopolysaccharides toxicity Liver drug effects Liver metabolism Macrophages, Peritoneal drug effects Macrophages, Peritoneal metabolism Mice Mice, Inbred ICR Mice, Knockout NF-E2-Related Factor 2 drug effects NF-E2-Related Factor 2 metabolism Organometallic Compounds pharmacology RAW 264.7 Cells Sepsis metabolism Sepsis pathology Anti-Inflammatory Agents, Non-Steroidal pharmacology Carbon Monoxide pharmacology Inflammation chemically induced Inflammation prevention & control Lipopolysaccharides antagonists & inhibitors NF-E2-Related Factor 2 genetics
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Research Support, Non-U.S. Gov't Language: English [Inflamm Res] 2015 Jul; Vol. 64 (7), pp. 537-48. <i>Date of Electronic Publication: </i>2015 Jun 07. MeSH Terms: Anti-Inflammatory Agents, Non-Steroidal / pharmacology ; Carbon Monoxide / pharmacology ; Inflammation / chemically induced ; Inflammation / prevention & control ; Lipopolysaccharides / antagonists & inhibitors ; NF-E2-Related Factor 2 / genetics ; Animals ; Brain / drug effects ; Brain / metabolism ; Cytokines / biosynthesis ; Female ; Lipopolysaccharides / toxicity ; Liver / drug effects ; Liver / metabolism ; Macrophages, Peritoneal / drug effects ; Macrophages, Peritoneal / metabolism ; Mice ; Mice, Inbred ICR ; Mice, Knockout ; NF-E2-Related Factor 2 / drug effects ; NF-E2-Related Factor 2 / metabolism ; Organometallic Compounds / pharmacology ; RAW 264.7 Cells ; Sepsis / metabolism ; Sepsis / pathology References: Antioxid Redox Signal. 2007 Nov;9(11):1963-70. (PMID: 17822364) ; Curr Pharm Des. 2004;10(8):879-91. (PMID: 15032691) ; Ann Clin Lab Sci. 2008 Summer;38(3):221-7. (PMID: 18715849) ; Mol Pharm. 2010 Dec 6;7(6):2185-93. (PMID: 20831192) ; Inhal Toxicol. 2010 Jul;22(8):648-56. (PMID: 20540623) ; J Exp Med. 2005 Dec 19;202(12 ):1703-13. (PMID: 16365149) ; Biochem Pharmacol. 2008 Oct 15;76(8):967-73. (PMID: 18755157) ; Am J Respir Crit Care Med. 2005 Feb 15;171(4):354-60. (PMID: 15557136) ; J Pharmacol Exp Ther. 2006 Sep;318(3):1315-22. (PMID: 16772536) ; Stroke. 2011 Sep;42(9):2605-10. (PMID: 21852618) ; MMWR Morb Mortal Wkly Rep. 1990 Jan 19;39(2):31-4. (PMID: 2104656) ; Am J Respir Cell Mol Biol. 2002 Dec;27(6):739-45. (PMID: 12444034) ; Crit Care Med. 2007 May;35(5):1244-50. (PMID: 17414736) ; Nat Rev Drug Discov. 2010 Sep;9(9):728-43. (PMID: 20811383) ; Nature. 2002 Dec 19-26;420(6917):885-91. (PMID: 12490963) ; J Biol Chem. 2003 Sep 26;278(39):36993-8. (PMID: 12857751) ; Mediators Inflamm. 2010;2010:238321. (PMID: 20862369) ; Int J Cancer. 2007 Nov 1;121(9):1883-91. (PMID: 17631644) ; J Exp Med. 2005 Jul 4;202(1):47-59. (PMID: 15998787) ; FASEB J. 2004 May;18(7):854-6. (PMID: 15001560) ; Clin Immunol. 2008 Sep;128(3):366-73. (PMID: 18614404) ; Cell Signal. 2001 Feb;13(2):85-94. (PMID: 11257452) ; Biochem Pharmacol. 2006 Nov 30;72(11):1439-52. (PMID: 16920072) ; Am J Physiol Gastrointest Liver Physiol. 2008 Jan;294(1):G184-91. (PMID: 17991708) ; Nat Med. 2000 Apr;6(4):422-8. (PMID: 10742149) ; Mutat Res. 2010 Aug 7;690(1-2):12-23. (PMID: 19799917) ; Biochem Biophys Res Commun. 2006 Dec 29;351(4):883-9. (PMID: 17097057) ; Br J Pharmacol. 2005 Jul;145(6):800-10. (PMID: 15880142) ; Nat Med. 2002 Mar;8(3):240-6. (PMID: 11875494) ; Cell. 2004 May 28;117(5):561-74. (PMID: 15163405) ; Am J Physiol Lung Cell Mol Physiol. 2001 Jul;281(1):L209-16. (PMID: 11404264) ; Trends Immunol. 2003 Aug;24(8):449-55. (PMID: 12909459) ; Curr Pharm Des. 2003;9(30):2525-39. (PMID: 14529551) ; N Engl J Med. 2003 Apr 17;348(16):1546-54. (PMID: 12700374) ; Natl Vital Stat Rep. 2008 Apr 24;56(10):1-120. (PMID: 18512336) ; Am J Physiol Heart Circ Physiol. 2006 May;290(5):H1862-70. (PMID: 16339837) ; J Biochem Mol Biol. 2004 Mar 31;37(2):139-43. (PMID: 15469687) ; Int Immunol. 1999 Feb;11(2):151-8. (PMID: 10069413) ; J Clin Invest. 2006 Apr;116(4):984-95. (PMID: 16585964) ; Am J Respir Crit Care Med. 2012 Apr 15;185(8):851-61. (PMID: 22312014) ; Cancer Res. 2006 Dec 15;66(24):11580-4. (PMID: 17178849) ; Br J Pharmacol. 2007 Apr;150(8):977-86. (PMID: 17339836) ; Pharmacol Rep. 2006;58 Suppl:132-44. (PMID: 17332683) Substance Nomenclature: 0 (Anti-Inflammatory Agents, Non-Steroidal) ; 0 (Cytokines) ; 0 (Lipopolysaccharides) ; 0 (NF-E2-Related Factor 2) ; 0 (Nfe2l2 protein, mouse) ; 0 (Organometallic Compounds) ; 0 (tricarbonyldichlororuthenium (II) dimer) ; 7U1EE4V452 (Carbon Monoxide) Entry Date(s): Date Created: 20150608 Date Completed: 20160307 Latest Revision: 20220712 Update Code: 20231215

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Nrf2 is essential for the anti-inflammatory effect of carbon monoxide in LPS-induced inflammation.